Esophageal cancer
Conditions
Interventions
Control group1:Intravenous neostigmine 0.04 mg/kg in combination with atropine 0.5 mg, while stopping intravenous pumping of anaesthetic drugs
Control group2:Intravenous neostigmine 0.04 mg/kg in combination with atropine 0.5 mg, with continued pumping of anaesthetic drugs
Experimental group:Intravenous sugammadex 2 mg/kg
Sponsors
Affiliated Cancer Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Select patients undergoing thoracoscopic laparoscopy combined with radical esophagectomy under general anesthesia; 2. Gender is not limited; 3. Aged 40 to 75 years; 4. ASA I-II grade.
Exclusion criteria
Exclusion criteria: 1. Body Mass Index (BMI) 25 kg/m2; 2. Systemic diseases such as coronary heart disease, asthma, nervous system diseases; 3. Severe cardiopulmonary insufficiency, American Heart Association (NYHA) cardiac function class >= grade III, severe dyspnea, cyanosis, abnormal respiratory rate; 4. Severe liver and kidney dysfunction; 5. Those who are allergic to sugammadex sodium, rocuronium bromide and neostigmine; 6. Pulmonary infection and atelectasis have been confirmed before surgery; 7. Patients with recurrent laryngeal nerve injury were identified before surgery; 8. Pregnant or lactating women; 9. Those who have used various oral contraceptives containing estrogen or progesterone within 1 month before surgery; 10. Patient refuses.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Residual neuromuscular block conditions;Time of extraction;Incidence of postoperative pulmonary complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of patients being transferred to ICU for observation and treatment;Post-operative recovery at 24H and 48H;Time of first post-operative bowel movement and defecation;Occurrence of postoperative bradycardia, nausea and vomiting and other adverse effects;Occurrence of complications such as paralytic intestinal obstruction; | — |
Countries
China
Contacts
Public ContactLyu Shuaiguo
Affiliated Cancer Hospital of Zhengzhou University
Outcome results
None listed